• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

粪便微生物群移植治疗复发性艰难梭菌感染。

Fecal microbiota transplantation for recurrent Clostridioides difficile infection.

机构信息

Midwestern University College of Pharmacy-Glendale, Glendale, AZ.

Department of Pharmacy Services, Banner Thunderbird Medical Center, Glendale, AZ.

出版信息

Am J Health Syst Pharm. 2019 Jun 18;76(13):935-942. doi: 10.1093/ajhp/zxz078.

DOI:10.1093/ajhp/zxz078
PMID:31361890
Abstract

PURPOSE

Randomized controlled trials investigating the efficacy and safety of fecal microbiota transplantation (FMT) for recurrent Clostridioides difficile infection (CDI) are reviewed, and practical issues for pharmacists to consider are discussed.

SUMMARY

Eight randomized controlled trials evaluating the use of FMT for recurrent CDI were analyzed. The trials varied in the type of sample (fresh, frozen, lyophilized), route of administration (nasogastric tube, colonoscopy, enema, oral), and comparator agent (different type of FMT, vancomycin). Efficacy rates ranged from 43.8% to 96.2% with FMT, and safety data were relatively similar. With these favorable data, pharmacists are likely to be involved at multiple steps in the delivery of FMT to patients with recurrent CDI, including the procurement, documentation, and administration of various products and patient education.

CONCLUSION

FMT is an option for recurrent CDI that is supported by findings of randomized controlled trials, although a preferred method for the delivery remains to be defined. Pharmacists can play an important role in the successful management of patients with recurrent CDI who may benefit from FMT.

摘要

目的

综述了评估粪便微生物群移植(FMT)治疗复发性艰难梭菌感染(CDI)的疗效和安全性的随机对照试验,并讨论了药师需要考虑的实际问题。

摘要

分析了 8 项评估 FMT 治疗复发性 CDI 的随机对照试验。这些试验在样本类型(新鲜、冷冻、冻干)、给药途径(鼻胃管、结肠镜、灌肠、口服)和对照药物(不同类型的 FMT、万古霉素)方面存在差异。FMT 的疗效率在 43.8%至 96.2%之间,安全性数据相对相似。鉴于这些有利的数据,药剂师可能会在为复发性 CDI 患者提供 FMT 的多个步骤中发挥重要作用,包括采购、记录和管理各种产品以及患者教育。

结论

FMT 是复发性 CDI 的一种选择,得到了随机对照试验结果的支持,尽管仍需确定其首选的给药方法。药剂师可以在成功管理可能受益于 FMT 的复发性 CDI 患者方面发挥重要作用。

相似文献

1
Fecal microbiota transplantation for recurrent Clostridioides difficile infection.粪便微生物群移植治疗复发性艰难梭菌感染。
Am J Health Syst Pharm. 2019 Jun 18;76(13):935-942. doi: 10.1093/ajhp/zxz078.
2
Safety and preliminary efficacy of orally administered lyophilized fecal microbiota product compared with frozen product given by enema for recurrent Clostridium difficile infection: A randomized clinical trial.口服冻干粪便微生物群产品与灌肠冷冻产品治疗复发性艰难梭菌感染的安全性和初步疗效比较:一项随机临床试验。
PLoS One. 2018 Nov 2;13(11):e0205064. doi: 10.1371/journal.pone.0205064. eCollection 2018.
3
Fecal microbiota transplantation (FMT) for C. difficile infection, just say 'No'.粪便微生物群移植(FMT)治疗艰难梭菌感染,就说“不”。
Anaerobe. 2019 Dec;60:102092. doi: 10.1016/j.anaerobe.2019.102092. Epub 2019 Aug 28.
4
Fecal Microbiota Transplantation (FMT) with Colonoscopy Is Superior to Enema and Nasogastric Tube While Comparable to Capsule for the Treatment of Recurrent Clostridioides difficile Infection: A Systematic Review and Meta-Analysis.经结肠镜检查的粪便微生物移植(FMT)优于灌肠和鼻胃管,与胶囊治疗复发性艰难梭菌感染相当:系统评价和荟萃分析。
Dig Dis Sci. 2021 Feb;66(2):369-380. doi: 10.1007/s10620-020-06185-7. Epub 2020 Mar 12.
5
Fecal microbiota transplantation for the treatment of recurrent Clostridioides difficile (Clostridium difficile).粪便微生物移植治疗复发性艰难梭菌(艰难梭菌)。
Cochrane Database Syst Rev. 2023 Apr 25;4(4):CD013871. doi: 10.1002/14651858.CD013871.pub2.
6
Faecal microbiota transplantation in the treatment of recurrent intestinal Clostridioides difficile infection - a ten-year single-center experience.粪便微生物群移植治疗复发性肠道艰难梭菌感染 - 十年单中心经验。
Cas Lek Cesk. 2022 Summer;161(3-4):126-130.
7
Prevention of recurrent Clostridioides difficile infection: A systematic review of randomized controlled trials.预防复发性艰难梭菌感染:随机对照试验的系统评价。
Anaerobe. 2020 Feb;61:102098. doi: 10.1016/j.anaerobe.2019.102098. Epub 2019 Sep 4.
8
Fecal microbiota transplantation for treatment of recurrent C. difficile infection: An updated randomized controlled trial meta-analysis.粪便微生物群移植治疗复发性艰难梭菌感染:一项更新的随机对照试验荟萃分析。
PLoS One. 2019 Jan 23;14(1):e0210016. doi: 10.1371/journal.pone.0210016. eCollection 2019.
9
Long-term durability and safety of fecal microbiota transplantation for recurrent or refractory Clostridioides difficile infection with or without antibiotic exposure.粪菌移植治疗复发性或难治性艰难梭菌感染的长期耐久性和安全性:有无抗生素暴露的比较。
Eur J Clin Microbiol Infect Dis. 2019 Sep;38(9):1731-1735. doi: 10.1007/s10096-019-03602-2. Epub 2019 Jun 5.
10
Stability and efficacy of frozen and lyophilized fecal microbiota transplant (FMT) product in a mouse model of Clostridium difficile infection (CDI).冷冻和冻干粪便微生物群移植(FMT)产品在艰难梭菌感染(CDI)小鼠模型中的稳定性和疗效。
Anaerobe. 2017 Dec;48:110-114. doi: 10.1016/j.anaerobe.2017.08.003. Epub 2017 Aug 9.

引用本文的文献

1
Fecal microbiota transplantation in the metabolic diseases: Current status and perspectives.粪菌移植在代谢性疾病中的应用:现状与展望。
World J Gastroenterol. 2022 Jun 21;28(23):2546-2560. doi: 10.3748/wjg.v28.i23.2546.
2
Introduction of Colonic and Fecal Microbiota From an Adult Pig Differently Affects the Growth, Gut Health, Intestinal Microbiota and Blood Metabolome of Newborn Piglets.成年猪结肠和粪便微生物群的引入对新生仔猪的生长、肠道健康、肠道微生物群和血液代谢组有不同影响。
Front Microbiol. 2021 Feb 4;12:623673. doi: 10.3389/fmicb.2021.623673. eCollection 2021.
3
and Antibacterial Activities of a Novel Quinolone Compound, OPS-2071, against Clostridioides difficile.
新型喹诺酮化合物OPS-2071对艰难梭菌的抗菌活性
Antimicrob Agents Chemother. 2021 Mar 18;65(4). doi: 10.1128/AAC.01170-20.
4
Prevention of Infection and Associated Diarrhea: An Unsolved Problem.感染及相关腹泻的预防:一个未解决的问题。
Microorganisms. 2020 Oct 23;8(11):1640. doi: 10.3390/microorganisms8111640.